Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours

British Journal of Surgery

Volumn 93, Issue 7, 2006, Pages 836-843

  Bumming P ^a   Ahlman, H ^a   Andersson, J ^a   Meis Kindblom, J M ^a   Kindblom, L G ^a   Nilsson, B ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TREATMENT OUTCOME; TUMOR DIAGNOSIS; TUMOR RECURRENCE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 33745854434     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5350     Document Type: Article

References (29)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269.
2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
3. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-795.
4. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-8121.
5. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932.
6. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054-5058.
7. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484-495.
8. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
9. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423.
10. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
11. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
12. The American College of Surgeons Oncology Group website. http://www.acosog.org/studies [15 August 2005].
13. The European Organization for Research and Treatment of Cancer protocols database website. http://www.eortc.be/protoc/ [15 August 2005].
14. The Scandinavian Sarcoma Group website. http://www.ssg-org.net/ [15 August 2005].
15. Nilsson B, Bumming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005; 103: 821-829.
16. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-465.
17. Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 2005; 29: 1170-1176.
18. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours (6th edn). Wiley-Liss: New York, 2002.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1956; 153: 457-481.
20. Peto R, Pike MC. Conservatism of the approximation sigma (O-E) 2-E in the logrank test for survival data or tumor incidence data. Biometrics 1973; 29: 579-584.
21. Breslow NE, Day NE. Statistical methods in cancer research. In IARC Scientific Publication 32, the Design and Analysis of Cohort Studies, Breslow NE, Day NE (eds), vol. 2. International Agency for Research on Cancer: Lyons, 1987; 131-135.
22. Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972; 34: 187-220.
23. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
24. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20: 3898-3905.
25. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-389.
26. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90: 332-339.
27. Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-S71) era. Surgery 2003; 134: 656-665.
28. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000; 88: 66-74.
29. Bümming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89: 460-464.